Syncom Formulations (India) Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Syncom Formulations (India) Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 39.4 times by its yearly operating cash. Higher than 90% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 86% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹50Over the last 3 years, every ₹100 of reported profit came with ₹50 of operating cash.
Lower than 81% of Healthcare companies in India.
Self-Funding Ratio
2.5×Over the last 3 years its own operating cash covered its investment spending (capex) 2.5 times.
Higher than 74% of Healthcare companies in India.
Cash Locked Ratio
₹21For every ₹100 of sales, ₹21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹34 tied up three years earlier.
Less money tied up than 58% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹22Sales grew 117% in 3 years; of every extra ₹100 of sales, ₹22 became extra profit.
Higher than 67% of Healthcare companies in India.
Asset Productivity Ratio
+117% / +41%In 3 years sales changed by +117% while total assets changed by +41%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
39.4×Debt due within a year is covered 39.4 times by its yearly operating cash.
Higher than 90% of Healthcare companies in India.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Higher than 81% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 86% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 85% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Syncom Formulations (India) Limited owes ₹0.22 for every ₹1 it owns. Net profit rose 55% in the year to Mar 2026, and grew 56% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
23.5Investors pay ₹23.5 for every ₹1 of Syncom Formulations (India) Limited's yearly profit, lower than 76% of Healthcare companies in India.
P/B ratio
5.00The share price is 5.00 times Syncom Formulations (India) Limited's book value per share, higher than 54% of Healthcare companies in India.
Market cap
₹2,076 CrThe total market value of all of Syncom Formulations (India) Limited's shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹415 CrWhat Syncom Formulations (India) Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹4.41Net worth divided by the number of shares. The share price of ₹22.08 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
21.1%Syncom Formulations (India) Limited earned 21.1% on its shareholders' money over the last year, higher than 83% of Healthcare companies in India.
Owes vs Owns
0.22×Syncom Formulations (India) Limited owes ₹0.22 for every ₹1 it owns (low), lower than 79% of Healthcare companies in India.
Dividend yield
0.43%Syncom Formulations (India) Limited pays 0.43% of its share price as dividends a year, higher than 55% of dividend-paying Healthcare companies in India.
Revenue growth
+5%Revenue rose 5% in the year to Mar 2026, and grew 29% a year on average over 3 years.
Profit growth
+55%Net profit rose 55% in the year to Mar 2026, and grew 56% a year on average over 3 years.
Profit margin
15.9%Syncom Formulations (India) Limited keeps ₹16 of every ₹100 of revenue as net profit.
Cash quality
0.8×Cash from Syncom Formulations (India) Limited's business was 0.8× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
121.4×Syncom Formulations (India) Limited's operating profit covered its interest costs 121.4 times in the year to Mar 2026.
Cash vs debt
Net cashSyncom Formulations (India) Limited held ₹111 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Syncom Formulations (India) Limited's P/E ratio?
Investors pay ₹23.5 for every ₹1 of Syncom Formulations (India) Limited's yearly profit, lower than 76% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Syncom Formulations (India) Limited: ₹2,076 Cr ÷ ₹415 Cr (31 Mar 2026) = 5.0.
What is Syncom Formulations (India) Limited's return on equity?
Syncom Formulations (India) Limited earned 21.1% on its shareholders' money over the last year, higher than 83% of Healthcare companies in India.
How much does Syncom Formulations (India) Limited owe compared with what it owns?
Syncom Formulations (India) Limited owes ₹0.22 for every ₹1 it owns (low), lower than 79% of Healthcare companies in India.
Does Syncom Formulations (India) Limited pay a dividend?
Yes. Syncom Formulations (India) Limited pays 0.43% of its share price as dividends a year, higher than 55% of dividend-paying Healthcare companies in India.
Is Syncom Formulations (India) Limited's revenue growing?
Revenue rose 5% in the year to Mar 2026, and grew 29% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.